atezolizumab plus SoC (n=201) vs. placebo plus SoC (n=202)
randomized controlled trial
atezolizumab (as induction and maintenance therapy) plus carboplatin and etoposide
atezolizumab (at a dose of 1200 mg, administered intravenously on day 1 of each cycle) and(induction phase, four 21-day cycles of carboplatin (area under the curve of 5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle))
placebo plus carboplatin and etoposide
carboplatin and etoposide (induction phase, four 21-day cycles of carboplatin (area under the curve of 5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle))
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
no information about EGFR or ALK status
double-blind
106 sites in 21 countries
P3/ two sided and one interim analysis. Alpha split between coprimary endpoint and reallocation possible
The addition of atezolizumab to chemotherapy in the first-line treatment of extensive- stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.